fenoflox vet 100 mg/ml injektioneste, liuos
chanelle pharmaceuticals manufacturing limited - enrofloxacin - injektioneste, liuos - 100 mg/ml - enrofloksasiini
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektiiviset immunosuppressantit - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
econor
elanco gmbh - valnemuliini - antiinfectives järjestelmälliseen käyttöön - pigs; rabbits - pigsthe hoito ja ennaltaehkäisy sikadysenterian. sian proliferatiivisen enteropatian (ileitis) kliinisten oireiden hoito. sikojen paksusuolen spiroketatoosin (koliitti) kliinisten oireiden ennaltaehkäisy, kun tauti on diagnosoitu karjassa. sian keuhkoahtaumataudin hoito ja ehkäisy. suositellulla annoksella 10-12 mg/kg ruumiinpainoa keuhkovauriot ja painonlasku vähenevät, mutta mykoplasmainfektio mycoplasma hyopneumoniae ei ole eliminoitu. rabbitsreduction kuolleisuus epidemian aikana kani epitsoottisen suolisairaus (ere). hoito on aloitettava varhaisessa vaiheessa, kun ensimmäinen kani on diagnosoitu taudin kliinisesti.
movicol jauhe oraaliliuosta varten, annospussi
norgine healthcare b.v. - potassium chloride, macrogol 3350, sodium bicarbonate, sodium chloride - jauhe oraaliliuosta varten, annospussi - makrogoli
asacol 1 g peräruiske
tillotts pharma ab - mesalazine - peräruiske - 1 g - mesalatsiini
movicol chocolate jauhe oraaliliuosta varten, annospussi
norgine healthcare b.v. - potassium chloride, macrogol 3350, sodium chloride, sodium hydrogen carbonate - jauhe oraaliliuosta varten, annospussi - makrogoli
asacol 500 mg peräpuikko
tillotts pharma ab - mesalazine - peräpuikko - 500 mg - mesalatsiini
movicol junior chocolate jauhe oraaliliuosta varten, annospussi
norgine healthcare b.v. - potassium chloride, macrogol 3350, sodium bicarbonate, sodium chloride - jauhe oraaliliuosta varten, annospussi - makrogoli
movicol junior plain jauhe oraaliliuosta varten, annospussi
norgine healthcare b.v. - potassium chloride, macrogol 3350, sodium bicarbonate, sodium chloride - jauhe oraaliliuosta varten, annospussi - makrogoli
movicol ready to take oraaliliuos, annospussi
norgine healthcare b.v. - potassium chloride, macrogol 3350, sodium chloride, sodium hydrogen carbonate - oraaliliuos, annospussi - makrogoli